NASDAQ:GNMK

GenMark Diagnostics Competitors

$24.01
+0.02 (+0.08 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.99
Now: $24.01
$24.03
50-Day Range
$17.88
MA: $22.21
$24.17
52-Week Range
$7.00
Now: $24.01
$24.25
Volume1.24 million shs
Average Volume2.71 million shs
Market Capitalization$1.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.02

Competitors

GenMark Diagnostics (NASDAQ:GNMK) Vs. GMED, INSP, IART, HAE, TNDM, and NVRO

Should you be buying GNMK stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to GenMark Diagnostics, including Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), Haemonetics (HAE), Tandem Diabetes Care (TNDM), and Nevro (NVRO).

GenMark Diagnostics (NASDAQ:GNMK) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Institutional & Insider Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 64.4% of Globus Medical shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by insiders. Comparatively, 25.6% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares GenMark Diagnostics and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Globus Medical12.36%9.85%9.04%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GenMark Diagnostics and Globus Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Globus Medical041002.71

GenMark Diagnostics presently has a consensus target price of $22.0125, indicating a potential downside of 8.32%. Globus Medical has a consensus target price of $66.40, indicating a potential downside of 4.80%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than GenMark Diagnostics.

Earnings & Valuation

This table compares GenMark Diagnostics and Globus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.94$-47,350,000.00($0.82)-29.28
Globus Medical$785.37 million8.86$155.21 million$1.6841.52

Globus Medical has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

GenMark Diagnostics has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Summary

Globus Medical beats GenMark Diagnostics on 11 of the 14 factors compared between the two stocks.

Inspire Medical Systems (NYSE:INSP) and GenMark Diagnostics (NASDAQ:GNMK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Volatility & Risk

Inspire Medical Systems has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500.

Institutional and Insider Ownership

96.3% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 96.9% of GenMark Diagnostics shares are owned by institutional investors. 6.6% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 3.3% of GenMark Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Inspire Medical Systems and GenMark Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspire Medical Systems-61.07%-32.23%-26.42%
GenMark Diagnostics-16.95%-39.36%-13.02%

Analyst Ratings

This is a summary of current ratings and recommmendations for Inspire Medical Systems and GenMark Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspire Medical Systems03702.70
GenMark Diagnostics05002.00

Inspire Medical Systems presently has a consensus price target of $168.5455, suggesting a potential downside of 27.18%. GenMark Diagnostics has a consensus price target of $22.0125, suggesting a potential downside of 8.32%. Given GenMark Diagnostics' higher possible upside, analysts plainly believe GenMark Diagnostics is more favorable than Inspire Medical Systems.

Valuation and Earnings

This table compares Inspire Medical Systems and GenMark Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspire Medical Systems$82.05 million76.64$-33,240,000.00($1.40)-165.33
GenMark Diagnostics$88.02 million19.94$-47,350,000.00($0.82)-29.28

Inspire Medical Systems has higher earnings, but lower revenue than GenMark Diagnostics. Inspire Medical Systems is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

GenMark Diagnostics beats Inspire Medical Systems on 8 of the 14 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Institutional & Insider Ownership

96.9% of GenMark Diagnostics shares are owned by institutional investors. Comparatively, 85.7% of Integra LifeSciences shares are owned by institutional investors. 3.3% of GenMark Diagnostics shares are owned by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

GenMark Diagnostics has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Valuation and Earnings

This table compares GenMark Diagnostics and Integra LifeSciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.94$-47,350,000.00($0.82)-29.28
Integra LifeSciences$1.52 billion4.02$50.20 million$2.7426.37

Integra LifeSciences has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GenMark Diagnostics and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Integra LifeSciences4.10%14.26%5.77%

Analyst Recommendations

This is a breakdown of recent ratings for GenMark Diagnostics and Integra LifeSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Integra LifeSciences14402.33

GenMark Diagnostics presently has a consensus price target of $22.0125, suggesting a potential downside of 8.32%. Integra LifeSciences has a consensus price target of $67.8889, suggesting a potential downside of 6.04%. Given Integra LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Integra LifeSciences is more favorable than GenMark Diagnostics.

Summary

Integra LifeSciences beats GenMark Diagnostics on 11 of the 14 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Profitability

This table compares GenMark Diagnostics and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Haemonetics11.76%22.85%10.40%

Earnings and Valuation

This table compares GenMark Diagnostics and Haemonetics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.94$-47,350,000.00($0.82)-29.28
Haemonetics$988.48 million6.01$76.53 million$3.3135.34

Haemonetics has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

GenMark Diagnostics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Institutional and Insider Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for GenMark Diagnostics and Haemonetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Haemonetics00403.00

GenMark Diagnostics currently has a consensus target price of $22.0125, indicating a potential downside of 8.32%. Haemonetics has a consensus target price of $144.80, indicating a potential upside of 23.79%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics is more favorable than GenMark Diagnostics.

Summary

Haemonetics beats GenMark Diagnostics on 10 of the 14 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for GenMark Diagnostics and Tandem Diabetes Care, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Tandem Diabetes Care04902.69

GenMark Diagnostics currently has a consensus target price of $22.0125, indicating a potential downside of 8.32%. Tandem Diabetes Care has a consensus target price of $115.9231, indicating a potential upside of 25.92%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than GenMark Diagnostics.

Earnings & Valuation

This table compares GenMark Diagnostics and Tandem Diabetes Care's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.94$-47,350,000.00($0.82)-29.28
Tandem Diabetes Care$362.30 million15.90$-24,750,000.00($0.22)-418.45

Tandem Diabetes Care has higher revenue and earnings than GenMark Diagnostics. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GenMark Diagnostics and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Tandem Diabetes Care-11.10%-10.98%-5.59%

Institutional & Insider Ownership

96.9% of GenMark Diagnostics shares are owned by institutional investors. Comparatively, 88.6% of Tandem Diabetes Care shares are owned by institutional investors. 3.3% of GenMark Diagnostics shares are owned by company insiders. Comparatively, 6.0% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

GenMark Diagnostics has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Summary

Tandem Diabetes Care beats GenMark Diagnostics on 10 of the 14 factors compared between the two stocks.

Nevro (NYSE:NVRO) and GenMark Diagnostics (NASDAQ:GNMK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Nevro and GenMark Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
GenMark Diagnostics-16.95%-39.36%-13.02%

Earnings and Valuation

This table compares Nevro and GenMark Diagnostics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million13.23$-103,690,000.00($3.37)-44.18
GenMark Diagnostics$88.02 million19.94$-47,350,000.00($0.82)-29.28

GenMark Diagnostics has lower revenue, but higher earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.9% of GenMark Diagnostics shares are owned by institutional investors. 7.6% of Nevro shares are owned by insiders. Comparatively, 3.3% of GenMark Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Nevro has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nevro and GenMark Diagnostics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
GenMark Diagnostics05002.00

Nevro presently has a consensus price target of $181.3846, indicating a potential upside of 21.84%. GenMark Diagnostics has a consensus price target of $22.0125, indicating a potential downside of 8.32%. Given Nevro's stronger consensus rating and higher probable upside, analysts plainly believe Nevro is more favorable than GenMark Diagnostics.


GenMark Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Globus Medical logo
GMED
Globus Medical
1.4$69.75+0.1%$6.96 billion$785.37 million75.82Analyst Revision
News Coverage
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$231.46+0.8%$6.29 billion$82.05 million-99.77
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$72.25+1.8%$6.11 billion$1.52 billion107.84Insider Selling
News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$116.97+1.4%$5.94 billion$988.48 million56.51
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$92.06+0.7%$5.76 billion$362.30 million-113.65
Nevro logo
NVRO
Nevro
1.2$148.87+2.2%$5.16 billion$390.26 million-54.73News Coverage
Inari Medical logo
NARI
Inari Medical
1.3$105.05+3.6%$5.12 billionN/A0.00News Coverage
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$138.27+1.3%$4.82 billion$42.93 million-68.45Insider Selling
Unusual Options Activity
News Coverage
ICU Medical logo
ICUI
ICU Medical
1.5$211.70+1.6%$4.49 billion$1.27 billion56.01Insider Selling
News Coverage
Glaukos logo
GKOS
Glaukos
0.9$85.02+1.0%$3.89 billion$236.98 million-51.53Analyst Upgrade
Cantel Medical logo
CMD
Cantel Medical
1.3$86.74+0.5%$3.67 billion$1.02 billion103.26News Coverage
NuVasive logo
NUVA
NuVasive
1.1$69.02+0.1%$3.55 billion$1.17 billion-313.73Insider Selling
Unusual Options Activity
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.78+0.7%$3.44 billion$994.85 million-116.56
AtriCure logo
ATRC
AtriCure
1.5$68.00+0.6%$3.10 billion$230.81 million-59.13News Coverage
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$90.94+0.2%$2.65 billion$214.55 million-47.61Analyst Report
Analyst Revision
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$59.83+0.1%$2.48 billion$13.82 million-30.53
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.74+3.1%$1.82 billion$4.11 million-6.43Analyst Report
News Coverage
Gap Up
Silk Road Medical logo
SILK
Silk Road Medical
1.1$52.97+3.2%$1.82 billion$63.35 million-43.42Insider Selling
News Coverage
Luminex logo
LMNX
Luminex
1.5$36.71+0.2%$1.74 billion$334.64 million94.13Analyst Downgrade
Alphatec logo
ATEC
Alphatec
0.8$16.77+2.7%$1.60 billion$113.43 million-15.25
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$38.98+1.9%$1.57 billion$236.54 million-59.06
Pulmonx logo
LUNG
Pulmonx
1.4$43.86+0.7%$1.57 billion$32.60 million0.00Insider Selling
Increase in Short Interest
News Coverage
MiMedx Group logo
MDXG
MiMedx Group
1.7$11.66+5.5%$1.30 billion$299.26 million-12.40
Atrion logo
ATRI
Atrion
1.1$669.80+1.9%$1.22 billion$155.07 million37.74
SI-BONE logo
SIBN
SI-BONE
1.2$34.09+0.1%$1.12 billion$67.30 million-21.31Increase in Short Interest
News Coverage
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.43+4.0%$1.07 billion$189.49 million-120.95
Cerus logo
CERS
Cerus
1.7$6.18+2.8%$1.04 billion$74.65 million-15.85Gap Down
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$50.49+0.8%$1.04 billion$117.23 million54.29
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$51.30+0.7%$1.01 billion$72.55 million-35.62
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.23+0.1%$924.06 million$264.16 million-5.42Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.79+0.6%$891.55 million$276.22 million-59.97Analyst Upgrade
News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.17+1.2%$861.85 million$459.95 million36.81News Coverage
Surmodics logo
SRDX
Surmodics
1.3$58.19+1.6%$800.46 million$94.86 million727.38News Coverage
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.01+0.0%$720.18 million$154.60 million-43.52
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.01+3.0%$674.33 million$123.86 million66.84
Intersect ENT logo
XENT
Intersect ENT
1.7$19.98+0.9%$659.66 million$109.14 million-10.46
Vapotherm logo
VAPO
Vapotherm
1.5$22.39+2.8%$577.82 million$48.10 million-10.66News Coverage
Gap Down
SeaSpine logo
SPNE
SeaSpine
1.5$20.62+1.5%$576.43 million$159.08 million-12.35Analyst Upgrade
News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.21+1.6%$576.21 million$114.51 million-85.55News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.03+3.5%$548.61 millionN/A-9.26
Accuray logo
ARAY
Accuray
2.3$5.21+1.7%$484.00 million$382.93 million37.21News Coverage
Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.67+2.6%$447.07 million$14.26 million-9.99Analyst Upgrade
Increase in Short Interest
News Coverage
iCAD logo
ICAD
iCAD
1.7$17.79+4.1%$443.29 million$31.34 million-18.73Analyst Downgrade
Gap Down
Profound Medical logo
PROF
Profound Medical
1.6$20.17+1.7%$409.25 million$4.17 million-17.24
PAVmed logo
PAVM
PAVmed
1.4$4.92+1.2%$405.71 millionN/A-6.47
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.00+4.7%$389.38 million$24.95 million-27.27News Coverage
Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$50.89+1.8%$382.69 million$198.38 million25.45
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$17.94+7.4%$370.87 million$11.22 million-40.77
Acutus Medical logo
AFIB
Acutus Medical
1.3$12.89+4.5%$362.15 million$2.84 million0.00
Soliton logo
SOLY
Soliton
1.3$16.18+1.8%$343.02 millionN/A-21.57Analyst Revision
News Coverage
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.